The global non-invasive prenatal testing market is
anticipated to reach USD 5.5 billion by 2025, according to a new report by
Grand View Research, Inc. Evolution of prenatal testing in the form of
noninvasive tests that can serve as an intermediate step between serum
screening and invasive diagnostic testing to determine the likelihood of fetal
abnormality is expected to drive growth in the reproductive genetics industry
over the forecast period.
In addition, presence of payers such as Anthem and Blue Shield of
California that have endorsed cfDNA-based Noninvasive Prenatal Testing (NIPT)
for trisomies 13, 18, and 21 is expected to impact the adoption rate of these
tests, thereby resulting in increased revenue generation.
However, the projected NIPT-related price erosion in this market
is expected to continue, thus intensifying competition amongst the operating
participants, but restraining revenue generation to a certain extent.
Browse full research report on Non-Invasive Prenatal Testing
(NIPT) Market: https://www.grandviewresearch.com/industry-analysis/noninvasive-prenatal-testing-market
Further Key Findings fromthe Report Suggest:
- The market is segmented on the basis of the tests carried out
during the gestation period as 0-12 weeks, 13-24 weeks, and 25-36 weeks
- 13-24 weeks accounted for the largest share owing to the
presence of maximum number of the tests carried out in this phase of
pregnancy
- High & average risk pregnancy held the larger share owing
to presence of favorable payer reimbursement in this segment
- Rising awareness pertaining to the prevention and screening
of chromosomal anomalies, such as Down Syndrome is another factor
anticipated to impact adoption
- Asia Pacific is expected to register fastest year-on-year
progress owing to the gradually increasing average maternal age, &
increasing incidence of chromosomal aneuploidies
- Some of the key players operating the market space include
Natera, Inc;Illumina, Inc; Sequenom; Roche (Ariosa Diagnostics); Quest
Diagnostics; and LabCorp
- One of the key trends followed by companies includes
licensing of the test to other labs and generating significant revenue by
collecting royalty payments
Browse
request sample of this report by Grand View Research: https://www.grandviewresearch.com/industry-analysis/noninvasive-prenatal-testing-market/request/rs1
Grand View Research has segmented the NIPT market on the basis of
gestation period, and pregnancy risk level:
Noninvasive Prenatal Testing Outlook, by Gestation Period
(Revenue, USD Million, 2014 - 2025)
- 0-12
weeks
- 13-24
weeks
- 25-36
weeks
Noninvasive Prenatal Testing Outlook, by Pregnancy Risk Level
(Revenue, USD Million, 2014 - 2025)
- High
& Average Risk
- Low
Risk
Noninvasive Prenatal Testing Regional Outlook (Revenue, USD
Million, 2014 - 2025)
- North
America
- U.S.
- Canada
- Europe
- Germany
- UK
- Asia
Pacific
- China
- Japan
- Latin
America
- Brazil
- MEA
- South
Africa
About
Grand View Research
Grand View Research, Inc. is a U.S.
based market research and consulting company, registered in the State of
California and headquartered in San Francisco. The company provides syndicated
research reports, customized research reports, and consulting services. To help
clients make informed business decisions, we offer market intelligence studies
ensuring relevant and fact-based research across a range of industries, from
technology to chemicals, materials and healthcare.
For
more info visit @ https://www.grandviewresearch.com
No comments:
Post a Comment